Rani Therapeutics Holdings (RANI) Total Debt (2020 - 2025)

Rani Therapeutics Holdings has reported Total Debt for 6 years, with the latest figure at $13.5 million in Q3 2025.

• On a quarterly basis, Total Debt fell 52.17% year-over-year to $13.5 million in Q3 2025; TTM through Sep 2025 was $13.5 million, a 52.17% decrease from a year earlier, with the FY2024 full-year figure at $24.6 million, down 16.23% from the prior year.
• Total Debt was $13.5 million for Q3 2025 at Rani Therapeutics Holdings, down from $17.2 million in the prior quarter.
• The five-year high for Total Debt was $29.5 million in Q2 2024, with the low at $30000.0 in Q2 2022.
• Average Total Debt over 5 years is $18.3 million, with a median of $22.8 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Total Debt slumped 99.37% in 2022, then jumped 97450.0% in 2023.
• Over 5 years, Total Debt stood at $126000.0 in 2021, then surged by 23076.19% to $29.2 million in 2022, then gained by 0.61% to $29.4 million in 2023, then fell by 16.23% to $24.6 million in 2024, then sank by 45.0% to $13.5 million in 2025.
• The last three Total Debt figures came in at $13.5 million (Q3 2025), $17.2 million (Q2 2025), and $20.9 million (Q1 2025), per Business Quant data.